Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
NCT04430894Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2020
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, isatuximab, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Started Jul 2020; status: active, not recruiting.
02
Drugs
carfilzomibisatuximablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04430894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430894.